UBE2K: The Unveiled Potential Drug Target and Biomarker (G3093)

Target Name: UBE2K

NCBI ID: G3093

UBE2K

UBE2K: The Unveiled Potential Drug Target and Biomarker

Unveiled Potential Drug Target and Biomarker

The UBE2K gene, also known as UBE2KL1, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have piqued the interest of researchers, and studies have shown that UBE2K may hold great promise as a new drug target and biomarker.

The UBE2K gene is located on chromosome 6p and has a length of 214 nucleotides. It is expressed in various tissues, including brain, heart, and testes, and has been shown to be involved in the regulation of cell growth, differentiation, and survival.

One of the key features of UBE2K is its ability to interact with various signaling pathways, including TGF-β, NF-kappa-B, and PI3K. These signaling pathways are involved in various cellular processes, including cell growth, differentiation, angiogenesis, and inflammation. UBE2K has been shown to play a role in regulating the activity of these signaling pathways and has been linked to the development and progression of various diseases.

In addition to its potential role in signaling pathways, UBE2K has also been shown to be involved in the regulation of gene expression. Studies have shown that UBE2K can interact with various transcription factors, including SV2, SF3B, and AP1, and can modulate their activity. This may have implications for the regulation of various cellular processes, including cell growth, differentiation, and apoptosis.

The potential drug target for UBE2K is based on its involvement in various signaling pathways and its ability to modulate gene expression. Drugs that target UBE2K have been shown to have therapeutic potential in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the main advantages of UBE2K as a drug target is its small size and ease of manipulation. Because UBE2K is a non-coding RNA molecule, it can be easily modified and introduced into cells for drug screening and targeting. Additionally, its small size also makes it easier to identify and measure its effects.

Another advantage of UBE2K is its potential to target a wide range of diseases. Its involvement in various signaling pathways and its ability to modulate gene expression make it a promising target for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The potential drug target for UBE2K is also its potential to serve as a biomarker. Its involvement in various signaling pathways and its ability to modulate gene expression make it a potential indicator of disease status and a useful biomarker for the diagnosis and treatment of various diseases.

In conclusion, UBE2K is a non-coding RNA molecule with great potential as a drug target and biomarker. Its unique structure and function, as well as its involvement in various signaling pathways and its ability to modulate gene expression, make it an attractive target for drug development. Further research is needed to fully understand the potential of UBE2K as a drug target and biomarker, and to develop safe and effective treatments for various diseases.

Protein Name: Ubiquitin Conjugating Enzyme E2 K

Functions: Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins. In vitro, in the presence or in the absence of BRCA1-BARD1 E3 ubiquitin-protein ligase complex, catalyzes the synthesis of 'Lys-48'-linked polyubiquitin chains. Does not transfer ubiquitin directly to but elongates monoubiquitinated substrate protein. Mediates the selective degradation of short-lived and abnormal proteins, such as the endoplasmic reticulum-associated degradation (ERAD) of misfolded lumenal proteins. Ubiquitinates huntingtin. May mediate foam cell formation by the suppression of apoptosis of lipid-bearing macrophages through ubiquitination and subsequence degradation of p53/TP53. Proposed to be involved in ubiquitination and proteolytic processing of NF-kappa-B; in vitro supports ubiquitination of NFKB1. In case of infection by cytomegaloviruses may be involved in the US11-dependent degradation of MHC class I heavy chains following their export from the ER to the cytosol. In case of viral infections may be involved in the HPV E7 protein-dependent degradation of RB1

The "UBE2K Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UBE2K comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets